Loading...
Axsome delivered solid revenue growth in Q2 2025, driven by continued momentum in AUVELITY and SUNOSI, and the launch of SYMBRAVO, while managing a reduced net loss year-over-year.
Axsome expects current cash to fund operations into cash flow positivity, with key regulatory submissions and clinical trial initiations planned for H2 2025.
Analyze how earnings announcements historically affect stock price performance